EBI-005: Phase Ib started

Eleven began a double-blind, placebo-controlled, U.S. Phase Ib trial to evaluate 5 and 20 mg/mL EBI-005 ophthalmic solution 3 times per day for 6 weeks in about 80 patients. ...